Tuesday, February 09, 2021 9:14:19 AM
https://www.indeed.com/m/viewjob?jk=8be5b1edf42d0766&from=serp&prevUrl=https%3A%2F%2Fwww.indeed.com%2Fm%2Fjobs%3FsameL%3D1%26q%3DAnavex%26l%3D%26from%3DsearchOnSerp
Clinical Research Scientist 5+yrs REQ in Pharma or Clinical Drug Dev.
Anavex Life Sciences
Remote•Temporarily remote
Job details
Salary
Up to $140,000 a year
Job Type
Full-time
Temporarily remote (COVID-19)
Qualifications
Bachelor's (Required)
Clinical Trials: 7 years (Required)
Clinical Research or Clinical Scientist: 5 years (Required)
Full Job Description
Clinical Research Scientist – Job Description
Overview:
The Clinical Research Scientist (CRS) position serves a key role within the Clinical Development R&D team, reporting to the Head of Clinical Research Science/Chief Medical Officer. The CRS works closely with the assigned study team(s) and medical director(s) to support the activities associated with one or more clinical studies. This position collaborates
with clinical team members as well as with functions outside of clinical to provide high quality and timely deliverables. The CRS is responsible for achievement of personal goals which support study team, project team, and corporate goals.
Responsibilities:
Lead or support assigned study level activities for 1 or more clinical studies with minimal supervision; may lead or co-lead a study.
Thorough understanding of assigned protocol and protocol requirements.
Support study start-up/conduct/close-out activities as applicable.
Preparation, storage, maintenance of clinical documents.
Protocol development process with minimal guidance; including writing, reviewing, adjudication/resolution of cross functional comments, and ensuring high quality final document).
Performance of medical monitoring duties, under the supervision of medical director(s), depending on the qualifications and experience of the candidate. Should be appropriately trained and fully aware of all aspects of the drug under investigation and the requirements of the protocol, including any annexes and amendments. In order to function as a medical monitor, the candidate should have adequate medical, pharmaceutical, and/or scientific qualifications, and clinical trial experience.
Draft and review of Protocols, Informed Consent Forms (ICF), and related documents; review/support finalization of regional and site ICFs as needed; ensure high quality, appropriate reading level text, and alignment with protocol).
Draft, review, and coordination of Regulatory Documents (e.g., IB, Briefing Books, DSUR, regulatory responses).
Draft, review and validation of clinical study reports; thorough understanding the connection between the data and the clinical study report.
Plan site and CRA training; including logistics, materials and presentations.
Support country/site selection activities.
Collaboration with Clinical Operations for budget preparation, CRO scope of work, etc. (i.e., review and provide feedback on activities/instructions/deliverables related to study data, IVRS, central labs, patient reported outcomes).
Study committee (e.g., DMC) activities such as charters, meetings, presentation preparation.
Investigator Meeting and SIV planning/facilitation/presentation.
Activities related to data generation and validation, including CRF creation, clinical data review, communication as needed to resolve data queries, draft/update/review data review plans, support medical director(s) in data and analyses review (generation of reports, action plans, trend identification).
May support clinical development planning (assist with analysis of data and review of literature to support future planning).
Collaborate with study team members (Clinical/Medical, Clinical Operations, Data Management, Statistics, Drug Safety, IMSC, Regulatory Affairs, Translational Medicine and Project Management) to ensure that key milestones are met on time and with high quality.
Provide guidance and scientific expertise within team, across department, and across functions.
Lead the planning and preparations for external/stakeholder meetings (e.g., IMs).
Present data/information to external investigators or study staff (e.g., SIV presentations).
Identify and liaise with external partners.
Identify, escalate current/active/future issues; propose and enact solutions.
Education Requirements:
Bachelor’s degree with 7+ years; or PhD/MD/PharmD with 2 years relevant career experience.
Degree in the Life Sciences or significant experience in clinical development ( > 11 years).
5+ years of experience in clinical science, clinical research, or equivalent.
Proficient knowledge of GCP/ICH, drug development process, study design, statistics, clinical operations.
Proficient knowledge and skills to support program specific data review, trend identification, data interpretation.
Knowledge of medical, scientific and clinical research techniques in CNS therapeutic area.
Required Experience and Skills:
Pharmaceutical and/or clinical drug development experience.
Excellent oral (including presentation) and written communication, computer/ database management and project management skills.
Preferred Experience and Skills:
Neuroscience experience, preferably in neurodegenerative or neurodevelopmental disorders.
Ability to effectively communicate and collaborate across functions and job levels.
Ability to assimilate technical information quickly.
Routinely takes initiative.
Detail-oriented.
Strong sense of teamwork; ability to lead team activities.
Proficient in Medical Terminology and medical writing skills.
Proficient knowledge of the disease area(s), KOLs, indication(s), compound(s) under study (including MOA, PK/PD, biomarker & safety profile).
Recent AVXL News
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:05:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:06 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:31:07 PM
- Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/07/2024 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024 • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:01:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM